Biotech IPOs may still be a bright spot, but the light has dimmed
GenSight has been playing in one of the hottest sectors in biotech, developing new gene therapies for rare eye diseases. But the French biotech never could raise sufficient interest to complete an IPO in the U.S., so now it’s taking its business plan, its prestigious scientific advisers and its deep-pocket investors and trying the game on the Paris exchange, rolling out a much-reduced effort to bag $44 million.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.